ArticleAnnals of medicine2025
Combining IMWG GA and hematopoietic score to optimize the evaluation of dynamic chemotherapy tolerance in multiple myeloma.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy tolerance significantly affects treatment efficacy and survival in multiple myeloma (MM), especially among frail patients. The International Myeloma Working Group Geriatric Assessment (IMWG GA) is widely used for frailty assessment, but limitations remain. Dynamic and integrated assessment approaches may improve risk stratification and support personalized treatment.
methodsWe retrospectively analyzed 111 newly diagnosed MM patients treated at the Third Affiliated Hospital of Sun Yat-sen University (Jan 2018-Jun 2024). IMWG GA and Hematopoietic Score (HS) were assessed at baseline and follow-up. Static and dynamic frailty assessments were compared. Chemotherapy-related adverse events (AEs) were graded per CTCAE 5.0.
resultsChemotherapy tolerance and frailty status changed across cycles. Static assessments showed limited predictive value, while dynamic evaluation with IMWG GA and HS improved risk stratification. IMWG GA differentiated Fit vs. Frail patients for total AEs (HR = 1.81,
conclusionHemo-IMWG GA offers a dynamic, integrated approach for evaluating chemotherapy tolerance in MM. By combining functional and hematopoietic dimensions, it improves prediction of treatment-related toxicity-especially hematological AEs-and aids personalized treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.